Kathleen J Ramos1, Siddhartha G Kapnadak2, Miranda C Bradford3, Ranjani Somayaji4, Eric D Morrell2, Joseph M Pilewski5, Erika D Lease2, Michael S Mulligan6, Moira L Aitken2, Cynthia J Gries7, Christopher H Goss8. 1. Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA. Electronic address: ramoskj@uw.edu. 2. Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA. 3. Children's Core for Biomedical Statistics, Seattle Children's Research Institute, Seattle, WA. 4. Department of Medicine, University of Calgary, Calgary, AB, Canada. 5. Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 6. Department of Surgery, Division of Cardiothoracic Surgery, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA. 7. Advent Health Transplant Institute, Advent Health Hospital, Orlando, FL. 8. Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA; Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA; Children's Core for Biomedical Statistics, Seattle Children's Research Institute, Seattle, WA.
Abstract
BACKGROUND: Reduced BMI is an absolute contraindication for lung transplantation (LTx) at most centers in the United States. The objective of this study was to quantify post-LTx survival of moderate to severely underweight patients with cystic fibrosis (CF) (BMI < 17 kg/m2) in the United States relative to normal-weight recipients with CF and other frequently transplanted patient cohorts. METHODS: Using United Network for Organ Sharing Registry data (undergoing transplant from June 2005-November 2015), Kaplan-Meier estimates of median posttransplant survival were calculated for all patients with CF, COPD, and idiopathic pulmonary fibrosis (IPF), as well as low and normal weight CF subgroups. Cox regression modeling stratified according to transplant center assessed risk of posttransplant mortality in recipients with CF and a BMI < 17 kg/m2 compared with recipients with COPD (reference). RESULTS: Median posttransplant survival (95% CI) for CF, COPD, and IPF was 7.9 (7.2-8.6), 5.9 (5.6-6.2), and 5.5 (5.2-5.8) years, respectively. Although an absolute decrease was noted in posttransplant survival for recipients with CF and a BMI < 17 kg/m2, compared with those with CF and a BMI ≥ 17 kg/m2 (7.0 years [4.5-7.9] vs 8.2 years [7.3-9.0]), Cox modeling found no increased mortality risk (adjusted hazard ratio, 1.09; 95% CI, 0.90-1.32; P = .38). There was no difference in posttransplant mortality between patients with CF and a BMI < 17 kg/m2 and recipients with COPD and all BMIs (adjusted hazard ratio, 1.04; 95% CI, 0.86-1.25; P = .71). CONCLUSIONS: Transplant recipients with CF and a BMI < 17 kg/m2 had posttransplant survival rates comparable to those of other groups frequently undergoing transplantation. BMI < 17 kg/m2 as a single risk factor in the CF population should not be treated as an absolute contraindication to LTx.
BACKGROUND: Reduced BMI is an absolute contraindication for lung transplantation (LTx) at most centers in the United States. The objective of this study was to quantify post-LTx survival of moderate to severely underweight patients with cystic fibrosis (CF) (BMI < 17 kg/m2) in the United States relative to normal-weight recipients with CF and other frequently transplanted patient cohorts. METHODS: Using United Network for Organ Sharing Registry data (undergoing transplant from June 2005-November 2015), Kaplan-Meier estimates of median posttransplant survival were calculated for all patients with CF, COPD, and idiopathic pulmonary fibrosis (IPF), as well as low and normal weight CF subgroups. Cox regression modeling stratified according to transplant center assessed risk of posttransplant mortality in recipients with CF and a BMI < 17 kg/m2 compared with recipients with COPD (reference). RESULTS: Median posttransplant survival (95% CI) for CF, COPD, and IPF was 7.9 (7.2-8.6), 5.9 (5.6-6.2), and 5.5 (5.2-5.8) years, respectively. Although an absolute decrease was noted in posttransplant survival for recipients with CF and a BMI < 17 kg/m2, compared with those with CF and a BMI ≥ 17 kg/m2 (7.0 years [4.5-7.9] vs 8.2 years [7.3-9.0]), Cox modeling found no increased mortality risk (adjusted hazard ratio, 1.09; 95% CI, 0.90-1.32; P = .38). There was no difference in posttransplant mortality between patients with CF and a BMI < 17 kg/m2 and recipients with COPD and all BMIs (adjusted hazard ratio, 1.04; 95% CI, 0.86-1.25; P = .71). CONCLUSIONS: Transplant recipients with CF and a BMI < 17 kg/m2 had posttransplant survival rates comparable to those of other groups frequently undergoing transplantation. BMI < 17 kg/m2 as a single risk factor in the CF population should not be treated as an absolute contraindication to LTx.
Authors: C Schwebel; I Pin; D Barnoud; G Devouassoux; P Y Brichon; P Chaffanjon; O Chavanon; C Sessa; D Blin; M Guignier; X Leverve; C Pison Journal: Eur Respir J Date: 2000-12 Impact factor: 16.671
Authors: Jonathan P Singer; Eric R Peterson; Mark E Snyder; Patricia P Katz; Jeffrey A Golden; Frank D'Ovidio; Matthew Bacchetta; Joshua R Sonett; Jasleen Kukreja; Lori Shah; Hilary Robbins; Kristin Van Horn; Rupal J Shah; Joshua M Diamond; Nancy Wickersham; Li Sun; Steven Hays; Selim M Arcasoy; Scott M Palmer; Lorraine B Ware; Jason D Christie; David J Lederer Journal: Am J Respir Crit Care Med Date: 2014-11-01 Impact factor: 21.405
Authors: A Weimann; M Braga; L Harsanyi; A Laviano; O Ljungqvist; P Soeters; K W Jauch; M Kemen; J M Hiesmayr; T Horbach; E R Kuse; K H Vestweber Journal: Clin Nutr Date: 2006-05-15 Impact factor: 7.324
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Jay M Brahmbhatt; Travis Hee Wai; Christopher H Goss; Erika D Lease; Christian A Merlo; Siddhartha G Kapnadak; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2022-05-20 Impact factor: 13.569
Authors: Ann L Jennerich; Joseph B Pryor; Travis Y Hee Wai; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos Journal: J Cyst Fibros Date: 2021-12-23 Impact factor: 5.527
Authors: Alyssa A Perez; Steven R Hays; Allison Soong; Ying Gao; John R Greenland; Lorriana E Leard; Rupal J Shah; Jeffrey Golden; Jasleen Kukreja; Aida Venado; Mary Ellen Kleinhenz; Jonathan P Singer Journal: Pediatr Pulmonol Date: 2020-04-01
Authors: Kathleen J Ramos; Jenna Sykes; Sanja Stanojevic; Xiayi Ma; Joshua S Ostrenga; Aliza Fink; Bradley S Quon; Bruce C Marshall; Albert Faro; Kristofer Petren; Alexander Elbert; Christopher H Goss; Anne L Stephenson Journal: Chest Date: 2021-04-17 Impact factor: 10.262
Authors: Joseph B Pryor; Miranda C Bradford; Ann L Jennerich; Travis Y Hee Wai; Joseph M Pilewski; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos Journal: Ann Am Thorac Soc Date: 2022-07